Table 7.

Select Tumor Antigens and Their Targeting Ligands

Disease	Molecular Target	Targeting Ligand	Lipid Used	In Vitro Test	In Vivo Test
Breast cancer	HER-2	SP90	SP90–PEG–DSPE	–	+
	Estrogen receptor	Estrogen	ES–PEG–DSPE	+	+
	HER-2	mAb fragments	mAb–PEG–DSPE	+	+
	Surface nucleosomes	mAb 2C5	mAb–PEG3400–DSPE	+	+
Ovarian cancer	Gelactinase	Gelactinase peptides	CTT2–PEG3400–DSPE	–	+
	SSTR2	Octreotide	OCT–PEG–DSPE	+	+
	Alpha(v) beta(3) integrin	RGD peptides	RGD–PEG2000–DSPE	+	+
Lymphoma	CD22	HB22.7 (mAb)	mAb–DSPE–mPEG	–	+
	BAFF receptor	mBAFF	mBAFF–PEG–DSPE	+	+
	CD19	Anti-CD19-IgG2a	aCD19–DSPE–mPEG	+	+
Lung cancer	NSCLC cell line	SP5-2	SP5–PEG–DSPE	–	+
	LHRH receptor	Analog of LHRH peptide	LHRH–PEG–DSPE	–	+
Murine tumor	Transferrin receptor	Transferrin	Transferrin–DSPE–PEG	+	+
	FA receptors	Folic acid	FA–PEG–DSPE	–	+
	Alpha(v) beta(3) integrin	RGD tripeptides	RGD–PEG–DSPE	–	+
Prostate cancer	Sigma receptor	Anisamide	AA–PEG3400–DSPE	+	+
	EGFR	Anti-EGFR scFv C10	scFv–PEG–DSPE	+	–

+ stands for p < 0.05 or significant.

– stands for p > 0.05, insignificant or unspecified.

2C5, a monoclonal antibody that is a nucleosome-specific nonpathogenic antinuclear antibody; AA, anisamide; aCD19, antibody bound to CD19; CD19, cluster of differentiation 19; CD22, cluster of differentiation-22; CD19, cluster of differentiation-19; DSPE, distearoylphosphatidylcholine; EGFR, epidermal growth factor receptor; FA, folic acid; HER-2, human epidermal growth factor receptor 2; IgG2a, subclass of IgG; LHRH, luteinizing hormone-releasing hormone; mAB, monoclonal antibody; mBAFF, mutant soluble B-cell activating factor; NSCLC, nonsmall cell–lung carcinoma; PEG, polyethylene glycol; RGD, arginine–glycine–aspartate; anti-EGFR scFv C10, a novel anti-EGFR single-chain variable antibody fragment (scFv) generated from screening a phage antibody library; SSTR2, somatostatin receptor 2; SP90, a synthetic targeting peptide with a sequence of SMDPFLFQLLQ; and SP5-2, a synthetic peptide with a sequence TDSILRSYDWTY.